115
Views
3
CrossRef citations to date
0
Altmetric
Review

Prevalence of amphetamine-type stimulants use in Iran: a systematic review and meta-analysis

ORCID Icon, ORCID Icon, , , , , , & ORCID Icon show all
Pages 569-585 | Received 24 Jul 2020, Accepted 11 Jan 2021, Published online: 03 Mar 2021
 

ABSTRACT

Background and objective: The use of Amphetamine-Type Stimulants (ATS) is a major health concern after cannabis in the world. The study aimed to conduct a systematic review of the published articles on the prevalence of methamphetamine, ecstasy, and non-prescribed methylphenidate (Ritalin) use in Iran and to perform a meta-analysis on this subject.

Methods: PubMed, Scopus, Embase, Web of Science, and national Persian databases including SID, Magiran, and IranDoc were searched for articles published until July 31, 2019.

The pooled lifetime and 12-month prevalence and 95% confidence intervals of ATS use were calculated.

Results: Fifty-five articles were included in the meta-analysis. The pooled lifetime and 12-month prevalence of ATS use was 5.4% (95% CI: 4.9%-6.0%) and 2.4% (95% CI: 1.9%-2.9%), respectively. The pooled lifetime prevalence of methamphetamine, ecstasy and non-prescribed methylphenidate (Ritalin) use was 6.7% (95% CI: 4.9%-8.6%), 5.9% (95% CI: 4.9%-6.8%) and 16.4% (95% CI: 11.6%-21.2%), respectively.

Conclusion: In Iran, lifetime ATS use is of intermediate prevalence. However, it is higher than that of other countries. The findings of this review highlight the need for more attention to ATS use in young men in the west and northwest of Iran.

Disclosure statement

The authors declare no conflicts of interest.

Additional information

Funding

This research did not receive any specific grants from funding agencies in the public, commercial, or not-for-profit sector.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.